Waystar Holding Corp. Common Stock
WAY
$18.25
-0.71%
Waystar Holding Corp. is a provider of mission-critical cloud technology that transforms healthcare payments and revenue cycle management for providers, payers, and patients. The company operates as a specialized platform player in the healthcare information technology services industry, focusing on streamlining the complex, fragmented processes of claims, billing, and reimbursement. The current investor narrative is heavily influenced by its recent public listing in June 2024 and its subsequent financial performance, with attention focused on its transition to profitability, revenue growth trajectory, and its ability to execute as a newly public entity in a competitive and regulated healthcare technology landscape.…
WAY
Waystar Holding Corp. Common Stock
$18.25
Investment Opinion: Should I buy WAY Today?
Rating & Thesis: Hold. Waystar presents a high-risk, high-potential-reward situation where compelling fundamentals are clashing with disastrous technicals, requiring patience for a catalyst to bridge the gap. The unanimous analyst Buy ratings and implied upside from a forward P/E of 11.38x suggest significant latent value, but the current price momentum argues against immediate entry.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The forward P/E of 11.38x is reasonable for a company growing revenue at 24% YoY, 2) The robust free cash flow generation of $283.2M TTM provides a margin of safety, 3) The successful profitability turnaround from a $27.7M loss to a $20.0M profit in four quarters demonstrates operational execution, and 4) The stock is trading near its 52-week low of $20.35, which may act as a technical floor. However, these are counterbalanced by the severe -46.9% one-year decline and high short interest of 4.42.
Risks & Conditions: The two biggest risks are a break below $20.35 support triggering another leg down, and a deceleration in revenue growth below 15% YoY, which would undermine the forward valuation thesis. This Hold would upgrade to a Buy if the stock establishes a firm base above $22 and shows two consecutive quarters of stable sequential revenue growth. It would downgrade to a Sell on a confirmed break below $20 with high volume. Relative to its own history and the growth it projects, the stock appears fairly valued to slightly undervalued on a forward basis, but remains overvalued on a trailing basis until earnings catch up to expectations.
Sign up to view all
WAY 12-Month Price Forecast
The AI assessment is neutral based on the high-conviction clash between improving fundamentals and catastrophic price action. The strong free cash flow and profitability turnaround provide a tangible foundation for value, but the stock is a clear victim of negative momentum and sentiment, trading like a broken story. Confidence is medium because the resolution hinges on an upcoming catalyst—likely the next earnings report—to determine whether fundamentals can regain control. The stance would upgrade to bullish on a confirmed reversal pattern and two quarters of stable execution; it would downgrade to bearish on a breakdown below $20, which would signal the fundamentals are indeed deteriorating to match the price action.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waystar Holding Corp. Common Stock's 12-month outlook, with a consensus price target around $23.73 and implied upside of +30.0% versus the current price.
Average Target
$23.73
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$15 - $24
Analyst target range
Waystar is covered by at least 6 analysts, and institutional sentiment is overwhelmingly bullish, as evidenced by ten recent ratings from major firms all being Buy, Overweight, or Outperform equivalents, with one upgrade from Hold to Buy. The consensus recommendation is strongly Buy, and while a specific average target price is not provided in the data, the high level of institutional support and lack of sell ratings suggests analysts see significant upside from the current depressed price level. The strength of analyst conviction is notable, with a tight clustering of actions around the February/March 2026 period following earnings, and no downgrades in the sample; however, the absence of explicit price targets in the data limits the ability to quantify the expected upside or the range of assumptions, though the uniform bullish stance indicates a belief that the company's fundamental improvements and market position are not reflected in the current stock price.
Bulls vs Bears: WAY Investment Factors
The evidence presents a stark dichotomy between deteriorating price action and improving fundamentals. The bear side currently has stronger evidence in the near term, as the severe technical breakdown and extreme market underperformance reflect overwhelming negative sentiment that has overpowered the company's solid operational progress. The single most important tension in the investment debate is whether the company's strong profitability turnaround and robust free cash flow generation can eventually overcome the deep-seated negative momentum and regain investor confidence, or if the technical damage and high short interest will continue to suppress the stock price despite improving fundamentals.
Bullish
- Strong Profitability Turnaround: The company has transitioned from a net loss of $27.69 million in Q2 2024 to a net income of $19.99 million in Q4 2025, achieving a net margin of 6.59%. This demonstrates successful execution of operating leverage and a clear path to sustainable profitability.
- Robust Revenue Growth: Q4 2025 revenue grew 24.35% year-over-year to $303.5 million, indicating strong underlying demand for its healthcare payments platform. This growth supports the company's scalable business model and market position.
- Exceptional Free Cash Flow Generation: The company generated $283.2 million in TTM free cash flow, providing significant internal funding for operations and growth. This strong cash generation, coupled with a manageable debt-to-equity ratio of 0.39, indicates a healthy financial foundation.
- Unanimous Analyst Bullishness: Analyst sentiment is overwhelmingly positive, with all recent ratings being Buy, Overweight, or Outperform equivalents. This strong institutional conviction suggests a belief that the current depressed stock price does not reflect the company's fundamental improvements.
Bearish
- Severe Technical Downtrend: The stock is down 46.91% over the past year and is trading at just 49.2% of its 52-week range, near its low of $20.35. This persistent negative momentum, including a 21.12% drop over the past three months, signals deep investor pessimism and a 'falling knife' scenario.
- Extreme Market Underperformance: WAY has underperformed the SPY by a massive 75.95% over the past year, indicating severe company or sector-specific headwinds. This extreme relative weakness suggests the stock is out of favor and faces significant selling pressure regardless of fundamentals.
- Elevated Trailing Valuation: Despite the price decline, the trailing P/E of 55.92x remains elevated, indicating the market still embeds high expectations for future profit expansion. Any earnings disappointment could trigger further multiple compression and price declines.
- Volatile Quarterly Revenue Growth: Sequential quarterly revenue in 2025 showed volatility ($256.4M, $270.7M, $268.7M, $303.5M), with a dip in Q3. This inconsistency raises questions about the predictability and sustainability of the 24% YoY growth rate.
WAY Technical Analysis
The prevailing price trend for WAY is a severe and sustained downtrend, with the stock down 46.91% over the past year and currently trading at just 49.2% of its 52-week range, based on a current price of $20.95 against a 52-week high of $42.55 and low of $20.35. This positioning near the absolute lows of its range suggests the stock is deeply oversold, presenting a potential value opportunity but also indicating significant negative momentum and a 'falling knife' scenario where further declines are possible. Recent momentum remains decisively negative, with the stock down 11.86% over the past month and 21.12% over the past three months, which aligns with and accelerates the longer-term downtrend; this persistent selling pressure is underscored by a massive 75.95% underperformance relative to the SPY over the past year, highlighting extreme sector-specific or company-specific headwinds. Key technical support is clearly defined at the 52-week low of $20.35, while resistance sits at the 52-week high of $42.55; a breakdown below the $20.35 support would signal a complete loss of the IPO price anchor and likely trigger another leg down, whereas any sustained move above the recent trading range would require a fundamental catalyst. The stock's volatility is extreme, as evidenced by a maximum drawdown of -49.1% within the provided data period, indicating it carries substantially higher risk than the broader market.
Beta
0.10
0.10x market volatility
Max Drawdown
-56.4%
Largest decline past year
52-Week Range
$18-$41
Price range past year
Annual Return
-52.4%
Cumulative gain past year
| Period | WAY Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +0.3% |
| 3m | -26.4% | +12.3% |
| 6m | -44.4% | +8.9% |
| 1y | -52.4% | +24.0% |
| ytd | -41.8% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAY Fundamental Analysis
Waystar's revenue trajectory shows solid growth, with Q4 2025 revenue of $303.5 million representing a 24.35% year-over-year increase; however, examining the sequential quarterly revenue from Q1 to Q4 2025 ($256.4M, $270.7M, $268.7M, $303.5M) reveals some volatility in growth pace, with a notable sequential dip in Q3 before a strong Q4 finish. The company has achieved profitability, reporting net income of $19.99 million in Q4 2025 and a net margin of 6.59%, while gross margin for the quarter was a healthy 56.16%; profitability has improved markedly from a net loss of $27.69 million in Q2 2024, demonstrating a successful turnaround story with expanding margins as operating leverage kicks in. The balance sheet and cash flow position appear stable, with a manageable debt-to-equity ratio of 0.39, a current ratio of 1.41 indicating sufficient short-term liquidity, and the generation of substantial free cash flow, with TTM free cash flow reported at $283.2 million; this strong cash generation, coupled with an ROE of 2.89%, suggests the company can fund its operations internally and is beginning to generate returns for equity holders, though the ROE level remains modest.
Quarterly Revenue
$303538000.0B
2025-12
Revenue YoY Growth
+0.24%
YoY Comparison
Gross Margin
+0.56%
Latest Quarter
Free Cash Flow
$283192000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAY Overvalued?
Given that Net Income is positive ($19.99M in latest quarter), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 55.92x, which is significantly higher than its forward PE of 11.38x; this wide gap implies the market is pricing in a substantial acceleration in earnings growth, aligning with analyst EPS estimates averaging $2.67 for the coming period. Compared to sector averages, Waystar's trailing PS ratio of 5.70x and EV/Sales of 4.69x are not directly comparable to a standard industry PE, but the forward PE of 11.38x suggests a valuation that could be in line with or at a discount to profitable tech services peers if growth expectations are met; the key justification for any premium would be its niche leadership in healthcare payments and its scalable platform model. Historically, the current trailing PE of 55.92x is below its own historical peak observed in recent quarters (e.g., 78.40x at the end of Q4 2025) but remains elevated compared to its post-IPO history, indicating that while some multiple compression has occurred with the price decline, the market still embeds expectations for future profit expansion rather than pricing in fundamental deterioration.
PE
55.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -106x~221x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Waystar's primary financial risk is its elevated valuation, with a trailing P/E of 55.92x demanding flawless execution of its growth trajectory to justify the multiple. While free cash flow is strong at $283.2M TTM, the volatile sequential revenue growth—including a dip in Q3 2025—introduces uncertainty about the sustainability of its 24% YoY growth rate. Furthermore, the company's modest Return on Equity of 2.89% suggests it is still in the early stages of generating efficient returns on shareholder capital, which may disappoint investors seeking immediate profitability traction.
Market & Competitive Risks: The stock faces severe valuation compression risk, having already undergone a -49.1% maximum drawdown, yet still trading at a premium trailing multiple. Its catastrophic 75.95% underperformance versus the SPY over the past year indicates it is deeply out of favor, likely due to sector rotation away from recent IPOs or growth stocks in a higher-rate environment. As a newly public entity in the competitive healthcare IT landscape, any misstep in customer acquisition or platform integration could be punished harshly by the market, as evidenced by the persistent selling pressure.
Worst-Case Scenario: The worst-case scenario involves a breakdown below the critical $20.35 support level, which represents the 52-week low. This could be triggered by a Q1 2026 earnings miss, a guidance reduction, or a loss of a major client, validating bearish sentiment and leading to a wave of analyst downgrades. In this adverse scenario, the stock could realistically re-test its IPO lows or fall further, representing a potential downside of -15% to -25% from the current $20.95 price, pushing it toward the $16-$18 range based on historical panic-selling patterns for fallen growth stocks.
FAQ
The key risks are, in order of severity: 1) Technical & Sentiment Risk: The stock is in a severe downtrend, down 46.9% in a year, and could break below its $20.35 support, leading to another leg down. 2) Execution Risk: The company must consistently deliver on its growth and profit targets to justify its forward multiple; any stumble could cause a sharp de-rating. 3) Competitive & Market Risk: Operating in the competitive healthcare IT sector, it faces pressure on pricing and customer acquisition, compounded by its 75.95% underperformance vs. the market indicating it is out of favor. 4) Liquidity Risk: High short interest of 4.42 can exacerbate both downside moves and create violent but unpredictable upside squeezes.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $24 and $30 as it stabilizes, meeting analyst EPS estimates. The Bull Case (30% probability) projects a rally to $35-$42 on stellar execution and a sentiment shift. The Bear Case (20% probability) warns of a drop to $16-$20 on a breakdown below support and an earnings miss. The most likely scenario is the Base Case, as it assumes the company executes adequately but remains burdened by its recent past. The key assumption is that the $20.35 support level holds, preventing a technical collapse.
WAY's valuation is bifurcated. On a trailing basis, it appears overvalued with a P/E of 55.92x, as this multiple prices in perfect future execution. On a forward basis, it appears undervalued or fairly valued, with a P/E of 11.38x based on analyst EPS estimates of $2.67, which is reasonable for a company growing revenue at 24%. Compared to its own history, the multiple has compressed from a peak of 78.40x. The current valuation implies the market expects solid earnings growth but remains skeptical, demanding a discount for the high execution risk and poor technical backdrop.
WAY is a speculative buy, not a good buy for all investors. For risk-tolerant investors seeking a high-potential turnaround, the current price near 52-week lows and a forward P/E of 11.38x offer an attractive entry point if one believes the company will hit its $2.67 EPS target. However, the severe -46.9% annual decline, high short interest of 4.42, and volatile revenue pattern make it a high-risk proposition. It is a good buy only for those who can stomach further downside to the $16-$18 range and are investing with a 12-18 month horizon to allow fundamentals to overcome negative sentiment.
WAY is unsuitable for short-term trading due to its extreme volatility (max drawdown of -49.1%) and negative momentum; traders would be fighting a strong downtrend. It is a candidate for a long-term, patient investment with a minimum horizon of 2-3 years, allowing time for the profitability turnaround to fully materialize in the financials and for market sentiment to potentially recover. The lack of a dividend and the company's growth-focused stage further support a long-term holding period. Investors should be prepared for significant price fluctuations along the way and only allocate capital they do not need in the near term.